Welcome to the Working Group on New TB Drugs Blog
Posted in Front Lines of TB R&D, TB R&D Spotlight Interviews, Uncategorized, Video, Voices from the Fight to Stop Tuberculosis
Immunotherapeutic Vaccines, TB and China: Interview with Dr. Douglas Lowrie
This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.
TB R&D Weekly Update: Tailoring TB Treatment Based on Host Genotype?
This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes. Additional links to TB R&D news are included.
International TB Research Roadmap Launched!
A plan targeting researchers around the world and providing them with a framework to achieve the research objectives of the the Global Plan to Stop TB 2011-2015 and beyond, towards elimination of TB, was launched on Saturday at the Union World Conference on Lung Health.
TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop
On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development. Additional links to TB R&D are included.
TB R&D Weekly Update: TB Drug Updates in Future Medicinal Chemistry
Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases. Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development. Additional links to TB R&D news are included.
TB R&D Weekly Update: T-Cell Surface Markers as Potential Biomarkers for TB Treatment
In this week’s article, potential cellular biomarkers are explored in the mouse model with three potential markers: PD-1 and TIM-3 on CD8 T cells and KIRG-1 on both CD4 and CD8 T cells. The search for validated biomarkers that can predict treatment success has been a difficult one. The focus of much of the research on biomarkers has been on serum markers, because of practical reasons and considerations of use in resource-limited settings. Henao-Tamayo, et al., took a different focus looking at markers on the surface of lung T cells. Additional links to TB R&D News are included.
Posted in Front Lines of TB R&D, TB Drug Development, TB R&D Spotlight Interviews, TB Treatment, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Dr. Edward Nardell
This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis. His principal academic appointment is as associate professor of medicine, Harvard Medical School. In 2002 he joined Partners In Health as Director of Tuberculosis Research. During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus. Additional links to TB R&D News are included.
Posted in Early Drug Development, Front Lines of TB R&D, TB Drug Development, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast interview on TB Drug Tolerance and Efflux Pumps
The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance during TB treatment which was published in the April 1 issue of Cell. Additional links to TB R&D News are included.
Posted in Front Lines of TB R&D, TB Drug Development, TB R&D Spotlight Interviews, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Eric Nuermberger
In this week”s TB R&D update, the WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled “PA-824 exhibits time-dependent activity in a murine model of tuberculosis” that we covered in a previous TB R&D Weekly Update. In the interview, Dr. Nuermberger provides an overview of his present research, key results presented in the article, and in vitro and preclinical testing of TB drug regimens. Also, links to additional news in TB R&D are included.
Posted in Front Lines of TB R&D, TB Drug Development, TB R&D Spotlight Interviews, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Anne Lenaerts
In this week”s TB R&D update, the WGND had the opportunity to talk with Dr. Lenaerts on a recent article published ahead of print in the Antimicrobial Agents and Chemotherapy journal in December 2010. Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology and Pathology. In the interview, Dr. Lenaerts provides an overview of her present research and the article, key recommendations for use of mouse models for testing TB drugs and the issue of relapse studies. Also, links to additional news in TB R&D are included.
-
Toppix TB News- TB, a neglected disease in Uganda 15 May 2013
- Dr. John: Medications, T.B, tinnitus 8 May 2013
- U.S. non-profit group to build tuberculosis center in Pyongyang 4 May 2013
- Predictors of tuberculosis (TB) and antiretroviral (ARV) medication... 26 Apr 2013
- Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr.... 26 Apr 2013
